Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2-early breast cancer: a correlative analysis of two phase II trials

CANCER RESEARCH(2023)

引用 0|浏览26
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要